Theralase Technologies Inc. (CVE:TLT – Get Free Report) shares fell 1.6% on Friday . The stock traded as low as C$0.29 and last traded at C$0.30. 41,605 shares changed hands during mid-day trading, a decline of 70% from the average session volume of 138,317 shares. The stock had previously closed at C$0.31.
Theralase Technologies Stock Down 1.6 %
The company’s fifty day simple moving average is C$0.27 and its 200-day simple moving average is C$0.22. The firm has a market capitalization of C$73.66 million, a PE ratio of -15.00 and a beta of 1.36. The company has a debt-to-equity ratio of 20.58, a current ratio of 1.21 and a quick ratio of 3.40.
Theralase Technologies Company Profile
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Featured Articles
- Five stocks we like better than Theralase Technologies
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- ServiceTitan Made Waves in Its IPO, But Is the Stock a Buy?
- Differences Between Momentum Investing and Long Term Investing
- Netflix: Is This the Perfect Time to Buy a Streaming Powerhouse?
- What is a Special Dividend?
- Goldman Sachs Unveils 3 Massive Opportunities for 2025 Investors
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
